A word in response to the corona virus crisis: Your print orders will be fulfilled, even in these challenging times. If you don’t want to wait – have a look at our ebook offers and start reading immediately.

Topics in Medicinal Chemistry

HCV: The Journey from Discovery to a Cure

Volume II

Editors: Sofia, Michael J. (Ed.)

Free Preview
  • Provides a comprehensive compilation of discoveries that led to the cure for HCV by the leading researchers in the field
  • Traces all aspects of HCV research that contributed to the development of key drugs and to the identification of important drug combinations
  • Provides an authoritative history of the journey to find a cure for HCV with accounts from the key researchers themselves
see more benefits

Buy this book

eBook $229.00
price for USA in USD (gross)
  • ISBN 978-3-030-28400-8
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $299.99
price for USA in USD
  • Customers within the U.S. and Canada please contact Customer Service at +1-800-777-4643, Latin America please contact us at +1-212-460-1500 (24 hours a day, 7 days a week). Pre-ordered printed titles are excluded from promotions.
  • Due: February 8, 2020
  • ISBN 978-3-030-28399-5
  • Free shipping for individuals worldwide
About this book

​Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) and infects approximately 75 million individuals worldwide. It is also one of the major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting antiviral drugs that led to cure rates approaching 100% in all patient populations after only 8-12 weeks of therapy. These efforts resulted in one of the greatest achievements in public health and provides the potential for eliminating HCV as a major disease worldwide.

This volume is aimed at a broad audience of academic and industrial scientists interested in the discovery and development of drugs to treat viral diseases and those interested in reading about one of the most unique accomplishments in biomedical research. The volume will provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is the companion book to the volume "HCV: The Journey from Discovery to a Cure - Volume I".

About the authors

Michael J. Sofia, Ph.D. is currently Chief Scientific Officer and co-founder at Arbutus Biopharma, Inc., a company focused on the discovery and development of therapies to treat hepatitis B. He also holds a professorship at the Baruch S. Blumberg Institute and an Adjunct Professorship at the Drexel University School of Medicine. 

Previously, Mike Sofia was Senior Vice President of Chemistry and Senior Advisor at Gilead Sciences and was Sr. Vice President of Chemistry at Pharmasset, Inc until Pharmasset’s acquisition by Gilead in Jan 2012.

Mike Sofia previously held research and research management positions at Bristol-Myers Squibb, Intercardia Research Labs (formerly Transcell Technologies) and  Eli Lilly & Co. He did his postdoctoral training in synthetic organic chemistry as an NIH fellow at Columbia University and received his Ph.D. in organic chemistry from the University of Illinois, Urbana-Champaign.  He earned his B.A. degree in chemistry from Cornell University.

Mike has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases. He is the principle inventor of sofosbuvir (Sovaldiâ and Harvoniâ) currently marketed as a treatment for the cure of HCV infection.  Mike is the recipient of numerous awards including the 2015 ACS Heroes of Chemistry Award, the Economist Magazine’s 2015 Innovation Award in Biosciences, the 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research and the 2017 Gertrude Elion Award from the International Society for Antiviral Research.

Table of contents (17 chapters)

Table of contents (17 chapters)
  • NS5A as a Target for HCV Drug Discovery

    Pages 3-25

    O’Boyle, Donald R., II (et al.)

  • The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex

    Pages 27-55

    Meanwell, Nicholas A. (et al.)

  • The Discovery of Ledipasvir (GS-5885): The Potent Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimen Harvoni®

    Pages 57-80

    Link, John O.

  • The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor in the Single-Tablet Regimens Epclusa and Vosevi®

    Pages 81-110

    Link, John O.

  • Discovery of Elbasvir

    Pages 111-131

    Coburn, Craig

Buy this book

eBook $229.00
price for USA in USD (gross)
  • ISBN 978-3-030-28400-8
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $299.99
price for USA in USD
  • Customers within the U.S. and Canada please contact Customer Service at +1-800-777-4643, Latin America please contact us at +1-212-460-1500 (24 hours a day, 7 days a week). Pre-ordered printed titles are excluded from promotions.
  • Due: February 8, 2020
  • ISBN 978-3-030-28399-5
  • Free shipping for individuals worldwide
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
HCV: The Journey from Discovery to a Cure
Book Subtitle
Volume II
Editors
  • Michael J. Sofia
Series Title
Topics in Medicinal Chemistry
Series Volume
32
Copyright
2019
Publisher
Springer International Publishing
Copyright Holder
Springer Nature Switzerland AG
eBook ISBN
978-3-030-28400-8
DOI
10.1007/978-3-030-28400-8
Hardcover ISBN
978-3-030-28399-5
Series ISSN
1862-2461
Edition Number
1
Number of Pages
VIII, 500
Number of Illustrations
30 b/w illustrations, 20 illustrations in colour
Topics